Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Antiviral Activity of Mericitabine (R7128) in Healthy Volunteers and Chronic HCV Patients
NCT00382798Phase 2Completed
- Sponsor
- Pharmasset Inc.
- Start
- Oct 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of mericitabine in hepatitis C (HCV) (8 arms), sponsored by Pharmasset Inc. Primary endpoints: Safety and Tolerability of RO5024048 at Day 56 and Pharmacokinetics of RO5024048 at Day 28. Started Oct 2006; status: completed.
02
Drugs
mericitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00382798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382798.